Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QLT Shows Off Its Assets In Hopes Of Attracting A Suitor

This article was originally published in The Pink Sheet Daily

Executive Summary

The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.

You may also be interested in...



QLT Gets New Lease On Life With Multi-Pronged Deals

The Canadian drug developer will be in a position to advance its lead retinoid asset and be an acquirer of choice, according to management, after completing a series of deals, including the acquisition of InSite Vision and an investment in a new company, Aralez Pharmaceuticals.

Auxilium Accepts Endo Offer, Dumps QLT Merger Plans

Endo seals the deal with Auxilium in a $2.6 billion acquisition that will add to its men’s health business and won’t prevent it from continuing on its M&A spree.

Auxilium Rejects Endo, But Is It Making A Play For More Cash?

Negotiations are likely to kick into high gear now that Auxilium officially has rejected Endo’s first offer of $2.2 billion. Auxilium is sticking to its QLT commitment, but the transaction holds little more than a tax-inversion play for the biotech.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel